BNP Paribas Financial Markets Increases Stake in Haemonetics Co. (NYSE:HAE)

BNP Paribas Financial Markets grew its position in Haemonetics Co. (NYSE:HAE - Free Report) by 95.9% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 33,209 shares of the medical instruments supplier's stock after buying an additional 16,260 shares during the period. BNP Paribas Financial Markets owned approximately 0.07% of Haemonetics worth $2,593,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. TD Waterhouse Canada Inc. purchased a new position in Haemonetics in the 4th quarter worth approximately $25,000. Covestor Ltd increased its holdings in shares of Haemonetics by 146.8% in the 4th quarter. Covestor Ltd now owns 738 shares of the medical instruments supplier's stock worth $58,000 after purchasing an additional 439 shares in the last quarter. Whittier Trust Co. purchased a new position in shares of Haemonetics in the fourth quarter worth $62,000. Parkside Financial Bank & Trust lifted its holdings in shares of Haemonetics by 25.6% during the fourth quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier's stock valued at $92,000 after purchasing an additional 240 shares in the last quarter. Finally, AlphaQuest LLC lifted its holdings in shares of Haemonetics by 36,520.0% during the fourth quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier's stock valued at $143,000 after purchasing an additional 1,826 shares in the last quarter. Institutional investors own 99.67% of the company's stock.

Haemonetics Price Performance

Shares of HAE traded down $0.94 during mid-day trading on Thursday, reaching $65.99. The stock had a trading volume of 32,769 shares, compared to its average volume of 696,696. The business has a fifty day moving average of $63.07 and a 200 day moving average of $71.15. The company has a debt-to-equity ratio of 1.35, a quick ratio of 2.55 and a current ratio of 3.97. The firm has a market cap of $3.31 billion, a price-to-earnings ratio of 25.97, a PEG ratio of 1.11 and a beta of 0.32. Haemonetics Co. has a 12 month low of $55.30 and a 12 month high of $94.99.

Haemonetics (NYSE:HAE - Get Free Report) last issued its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.24 earnings per share for the quarter, topping the consensus estimate of $1.22 by $0.02. The company had revenue of $330.60 million during the quarter, compared to the consensus estimate of $329.38 million. Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. Haemonetics's quarterly revenue was down 3.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.90 EPS. Equities analysts predict that Haemonetics Co. will post 4.55 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on HAE. Needham & Company LLC reduced their price objective on Haemonetics from $104.00 to $84.00 and set a "buy" rating for the company in a report on Thursday, May 8th. Raymond James reiterated a "strong-buy" rating and issued a $105.00 price target (down from $115.00) on shares of Haemonetics in a research note on Friday, May 9th. Bank of America downgraded shares of Haemonetics from a "neutral" rating to an "underperform" rating and lowered their price objective for the company from $95.00 to $68.00 in a research report on Friday, February 7th. StockNews.com downgraded shares of Haemonetics from a "buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Finally, Barrington Research decreased their target price on shares of Haemonetics from $108.00 to $95.00 and set an "outperform" rating for the company in a research note on Friday, February 7th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $97.89.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.